PBM reforms and regulatory changes have reshaped the industry landscape.

Policies that focus on earlier diagnosis, treatment initiation, and expanded access to treatment can further improve treatment and health equity impacts.

Treatment often involves a combination of preventive measures, topical therapies, and systemic treatments.

Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.

Lenora Newsome, PD, president of the National Association of Boards of Pharmacy, explores how pharmacists can support mental health.

Outpatient models are emerging as feasible alternatives to traditional inpatient care, offering potential benefits such as reduced hospitalization, improved social well-being, and cost savings.

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

An increase of shingles vaccination was reported among individuals with asthma.

This marks the first and only therapy to receive this designation for Sjögren disease, which currently has no approved treatment.

Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.

Increased global capacity for surveillance could help monitor seasonal influenza to reduce the risk of vaccine mismatch and inform effective interventions.

GNSC-001 is a first-in-class gene therapy designed to offer long-term relief of musculoskeletal diseases such as osteoarthritis.

Pharmacists can increase awareness about the value of monitoring glucose and the proper use of nonprescription blood glucose meters and continuous glucose monitors.

Abelacimab is an investigational, selective, fully human monoclonal antibody.

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

When compared to established diagnostic assays such as the basophil activation test, the Hoxb8 mast cell activation test demonstrates similar precision.

The encouraging results suggest this low-cost, scalable strategy should be considered for population-level outreach globally to improve flu vaccination rates.

The pipeline of hallucinogenic and nonhallucinogenic psychedelic medicines is exploding.

The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.

This quality improvement initiative demonstrates that pharmacies were unable to use performance reports provided by the payer to improve performance scores and decrease direct and indirect remuneration (DIR) fees.

Adaptability, teamwork, and a culture of lifetime learning are required virtues in our rapidly evolving medical landscape.

Twice-yearly dosing could significantly improve adherence rates.